Replies to post #20211 on Ayala Pharmaceuticals Inc (ADXS)

[hovacre]

Honestly I do not believe so. The WT1 approach used by SELLAS is thought to be more pristinely tumor specific, but in my understanding that has only worked as advertised in a select few cases.

I'm not pessimistic, but I don't personally feel that it will be comparable to CAR-T, which have a uniquely specific target. CD19 is only on B cells, so you have a pretty darn good idea what the B cell-related toxicity will be!